Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2011

01-07-2011 | Preclinical study

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth

Authors: Robert S. Tolhurst, Ross S. Thomas, Fiona J. Kyle, Hetal Patel, Manikandan Periyasamy, Andrew Photiou, Paul T. R. Thiruchelvam, Chun-Fui Lai, Marwa Al-sabbagh, Rosemary A. Fisher, Sayka Barry, Tatjana Crnogorac-Jurcevic, Lesley-Ann Martin, Mitch Dowsett, R. Charles Coombes, Tahereh Kamalati, Simak Ali, Laki Buluwela

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Login to get access

Abstract

Estrogen receptor-α (ERα) positive breast cancer frequently responds to inhibitors of ERα activity, such as tamoxifen, and/or to aromatase inhibitors that block estrogen biosynthesis. However, many patients become resistant to these agents through mechanisms that remain unclear. Previous studies have shown that expression of ERα in ERα-negative breast cancer cell lines frequently inhibits their growth. In order to determine the consequence of ERα over-expression in ERα-positive breast cancer cells, we over-expressed ERα in the MCF-7 breast cancer cell line using adenovirus gene transduction. ERα over-expression led to ligand-independent expression of the estrogen-regulated genes pS2 and PR and growth in the absence of estrogen. Interestingly, prolonged culturing of these cells in estrogen-free conditions led to the outgrowth of cells capable of growth in cultures from ERα transduced, but not in control cultures. From these cultures a line, MLET5, was established which remained ERα-positive, but grew in an estrogen-independent manner. Moreover, MLET5 cells were inhibited by anti-estrogens showing that ERα remains important for their growth. Gene expression microarray analysis comparing MCF-7 cells with MLET5 highlighted apoptosis as a major functional grouping that is altered in MLET5 cells, such that cell survival would be favoured. This conclusion was further substantiated by the demonstration that MLET5 show resistance to etoposide-induced apoptosis. As the gene expression microarray analysis also shows that the apoptosis gene set differentially expressed in MLET5 is enriched for estrogen-regulated genes, our findings suggest that transient over-expression of ERα could lead to increased cell survival and the development of estrogen-independent growth, thereby contributing to resistance to endocrine therapies in breast cancer patients.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combatting resistance. Nat Rev Cancer 2:101–112PubMedCrossRef Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combatting resistance. Nat Rev Cancer 2:101–112PubMedCrossRef
3.
go back to reference Johnston SR, Dowsett M (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3(11):821–831PubMedCrossRef Johnston SR, Dowsett M (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3(11):821–831PubMedCrossRef
4.
go back to reference Chen S et al (2006) What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 102(1–5):232–240PubMedCrossRef Chen S et al (2006) What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 102(1–5):232–240PubMedCrossRef
5.
go back to reference Kuukasjarvi T et al (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14(9):2584–2589PubMed Kuukasjarvi T et al (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14(9):2584–2589PubMed
6.
go back to reference Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3(1):85–94PubMedCrossRef Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3(1):85–94PubMedCrossRef
7.
go back to reference Gee JM et al (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95(4):247–254PubMedCrossRef Gee JM et al (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95(4):247–254PubMedCrossRef
8.
go back to reference Kirkegaard T et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207(2):139–146PubMedCrossRef Kirkegaard T et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207(2):139–146PubMedCrossRef
9.
go back to reference Sarwar N et al (2006) Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 13(3):851–861PubMedCrossRef Sarwar N et al (2006) Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 13(3):851–861PubMedCrossRef
10.
go back to reference Osborne CK et al (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353–361PubMedCrossRef Osborne CK et al (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353–361PubMedCrossRef
11.
go back to reference Jiang SY, Jordan VC (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84(8):580–591PubMedCrossRef Jiang SY, Jordan VC (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84(8):580–591PubMedCrossRef
12.
go back to reference Zajchowski DA, Sager R, Webster L (1993) Estrogen inhibits the growth of estrogen receptor-negative but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res 53(20):5004–5011PubMed Zajchowski DA, Sager R, Webster L (1993) Estrogen inhibits the growth of estrogen receptor-negative but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res 53(20):5004–5011PubMed
13.
go back to reference Lazennec G, Katzenellenbogen BS (1999) Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Mol Cell Endocrinol 149(1–2):93–105PubMedCrossRef Lazennec G, Katzenellenbogen BS (1999) Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Mol Cell Endocrinol 149(1–2):93–105PubMedCrossRef
14.
go back to reference Fowler AM et al (2004) Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB J 18(1):81–93PubMedCrossRef Fowler AM et al (2004) Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB J 18(1):81–93PubMedCrossRef
15.
go back to reference He TC et al (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95(5):2509–2514PubMedCrossRef He TC et al (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95(5):2509–2514PubMedCrossRef
16.
go back to reference Ali S et al (2009) The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res 69(15):6208–6215PubMedCrossRef Ali S et al (2009) The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res 69(15):6208–6215PubMedCrossRef
17.
go back to reference Buluwela L et al (2005) Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF. Gene Therapy 12(5):452–460PubMedCrossRef Buluwela L et al (2005) Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF. Gene Therapy 12(5):452–460PubMedCrossRef
18.
go back to reference Lavinsky RM et al (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95(6):2920–2925PubMedCrossRef Lavinsky RM et al (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95(6):2920–2925PubMedCrossRef
19.
go back to reference Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295(5564):2465–2468PubMedCrossRef Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295(5564):2465–2468PubMedCrossRef
20.
go back to reference Keeton EK, Brown M (2005) Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19(6):1543–1554PubMedCrossRef Keeton EK, Brown M (2005) Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19(6):1543–1554PubMedCrossRef
21.
go back to reference Hupperets PS et al (1997) The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer. Am J Clin Oncol 20(6):546–551PubMedCrossRef Hupperets PS et al (1997) The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer. Am J Clin Oncol 20(6):546–551PubMedCrossRef
22.
go back to reference Nielsen KV et al (2010) Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-0984-y Nielsen KV et al (2010) Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-0984-y
23.
go back to reference Moelans CB et al (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23(7):1029–1039PubMedCrossRef Moelans CB et al (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23(7):1029–1039PubMedCrossRef
24.
go back to reference Holst F et al (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39(5):655–660PubMedCrossRef Holst F et al (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39(5):655–660PubMedCrossRef
25.
go back to reference Tomita S et al (2009) Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 100(6):1012–1017PubMedCrossRef Tomita S et al (2009) Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 100(6):1012–1017PubMedCrossRef
26.
go back to reference Albertson DG (2008) Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat Genet 40(7):821–822PubMedCrossRef Albertson DG (2008) Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat Genet 40(7):821–822PubMedCrossRef
27.
go back to reference Anderson H et al (2007) Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 106(1–5):49–54PubMedCrossRef Anderson H et al (2007) Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 106(1–5):49–54PubMedCrossRef
28.
go back to reference Chan CM et al (2002) Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81(4–5):333–341PubMedCrossRef Chan CM et al (2002) Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81(4–5):333–341PubMedCrossRef
30.
go back to reference Brunner N et al (1993) Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53(2):283–290PubMed Brunner N et al (1993) Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53(2):283–290PubMed
31.
go back to reference Naughton C et al (2007) Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. Mol Endocrinol 21(11):2615–2626PubMedCrossRef Naughton C et al (2007) Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. Mol Endocrinol 21(11):2615–2626PubMedCrossRef
32.
go back to reference Zhang J et al (1998) Proteasomal regulation of nuclear receptor corepressor-mediated repression. Genes Dev 12(12):1775–1780PubMedCrossRef Zhang J et al (1998) Proteasomal regulation of nuclear receptor corepressor-mediated repression. Genes Dev 12(12):1775–1780PubMedCrossRef
33.
go back to reference Frasor J et al (2005) Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes. Proc Natl Acad Sci USA 102(37):13153–13157PubMedCrossRef Frasor J et al (2005) Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes. Proc Natl Acad Sci USA 102(37):13153–13157PubMedCrossRef
34.
go back to reference Shou J et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926–935PubMedCrossRef Shou J et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926–935PubMedCrossRef
35.
go back to reference Kirkegaard T et al (2007) Amplified in breast cancer 1 in human epidermal growth factor receptor—positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 13(5):1405–1411PubMedCrossRef Kirkegaard T et al (2007) Amplified in breast cancer 1 in human epidermal growth factor receptor—positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 13(5):1405–1411PubMedCrossRef
36.
go back to reference Martin LA et al (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278(33):30458–30468PubMedCrossRef Martin LA et al (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278(33):30458–30468PubMedCrossRef
37.
go back to reference Santen RJ, et al (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12(Suppl 1): S61–S73 Santen RJ, et al (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12(Suppl 1): S61–S73
38.
go back to reference Song RX et al (2005) Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis 10(3):667–678PubMedCrossRef Song RX et al (2005) Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis 10(3):667–678PubMedCrossRef
39.
go back to reference Callagy GM et al (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12(8):2468–2475PubMedCrossRef Callagy GM et al (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12(8):2468–2475PubMedCrossRef
40.
go back to reference Cannings E et al (2007) Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat 102(2):173–179PubMedCrossRef Cannings E et al (2007) Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat 102(2):173–179PubMedCrossRef
41.
go back to reference Coser KR et al (2009) Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA 106(34):14536–14541PubMedCrossRef Coser KR et al (2009) Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA 106(34):14536–14541PubMedCrossRef
Metadata
Title
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth
Authors
Robert S. Tolhurst
Ross S. Thomas
Fiona J. Kyle
Hetal Patel
Manikandan Periyasamy
Andrew Photiou
Paul T. R. Thiruchelvam
Chun-Fui Lai
Marwa Al-sabbagh
Rosemary A. Fisher
Sayka Barry
Tatjana Crnogorac-Jurcevic
Lesley-Ann Martin
Mitch Dowsett
R. Charles Coombes
Tahereh Kamalati
Simak Ali
Laki Buluwela
Publication date
01-07-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1122-6

Other articles of this Issue 2/2011

Breast Cancer Research and Treatment 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine